The US drug regulator issued seven observations after an eight-day inspection of Cipla’s Pithampur facility. The company said it will respond within the stipulated timeline.
The US drug regulator issued seven observations after an eight-day inspection of Cipla’s Pithampur facility. The company said it will respond within the stipulated timeline.